Shire plc Blocklisting - Interim Review

 
TIDMSHP 
 
BLOCK LISTING SIX MONTHLY RETURNMay 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)Name of applicant:Shire plcName of scheme:Shire Sharesave SchemePeriod of return:From:November 23, 2016To: May 22, 2017Balance of unallotted securities under scheme(s) from previous return:184,611Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):NilLess:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):17,079Equals:  Balance under scheme(s) not yet issued/allotted at end of period:167,532   Name of applicant:Shire plcName of scheme:Shire Portfolio Share PlanPeriod of return:From:November 23, 2016To:May 22, 2017Balance of unallotted securities under scheme(s) from previous return:769,615Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):NilLess:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):405,083Equals:  Balance under scheme(s) not yet issued/allotted at end of period:364,532   Name of applicant:Shire plcName of scheme:Shire Employee Stock Purchase PlanPeriod of return:From:November 23, 2016To:May 22, 2017Balance of unallotted securities under scheme(s) from previous return:244,057Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):NilLess:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):6,359Equals:  Balance under scheme(s) not yet issued/allotted at end of period:237,698   Name of applicant:Shire plcName of scheme:Shire Long Term Incentive Plan 2015Period of return:From:November 23, 2016To:May 22, 2017Balance of unallotted securities under scheme(s) from previous return:2,836,412Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):NilLess:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):145,740Equals:  Balance under scheme(s) not yet issued/allotted at end of period:2,690,672   Name of applicant:Shire plcName of scheme:Shire Global Employee Stock Purchase PlanPeriod of return:From:November 23, 2016To:May 22, 2017Balance of unallotted securities under scheme(s) from previous return:1,604,243Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):NilLess:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):3,400Equals:  Balance under scheme(s) not yet issued/allotted at end of period:1,600,843 
 Name of applicant:Shire plcName of scheme:Baxalta Exchange AwardsPeriod of return:From:November 23, 2016To:May 22, 2017Balance of unallotted securities under scheme(s) from previous return:20,488,204Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):NilLess:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):2,492,337Equals:  Balance under scheme(s) not yet issued/allotted at end of period:17,995,867   Name of contact:Sarah Rixon, Company Secretarial AssistantTelephone number of contact:01256 894000For further information please contact:Investor RelationsIan [e-mail][phone]Robert [e-mail][phone]MediaLisa [e-mail][phone]Debbi [e-mail] [phone]NOTES TO EDITORSAbout ShireShire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.www.shire.com 
 

(END) Dow Jones Newswires

May 23, 2017 07:10 ET (11:10 GMT)